Laboratory of Pharmacy and Pharmaceutical Technology, Networking Biomedical Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, SLFPB-EHU, Faculty of Pharmacy, University of the Basque Country, 01006, Vitoria-Gasteiz, Spain.
Med Res Rev. 2011 Mar;31(2):284-309. doi: 10.1002/med.20184.
Deciphering the function of proteins and their roles in signaling pathways is one of the main goals of biomedical research, especially from the perspective of uncovering pathways that may ultimately be exploited for therapeutic benefit. Over the last half century, a greatly expanded understanding of the biology of the glycoprotein hormone erythropoietin (Epo) has emerged from regulator of the circulating erythrocyte mass to a widely used therapeutic agent. Originally viewed as the renal hormone responsible for erythropoiesis, recent in vivo studies in animal models and clinical trials demonstrate that many other tissues locally produce Epo independent of its effects on red blood cell mass. Thus, not only its hematopoietic activity but also the recently discovered nonerythropoietic actions in addition to new drug delivery systems are being thoroughly investigated in order to fulfill the specific Epo release requirements for each therapeutic approach. The present review focuses on updating the information previously provided by similar reviews and recent experimental approaches are presented to describe the advances in Epo drug delivery achieved in the last few years and future perspectives.
解析蛋白质的功能及其在信号通路中的作用是生物医学研究的主要目标之一，特别是从揭示可能最终用于治疗获益的途径的角度来看。在过去的半个世纪中，糖蛋白激素促红细胞生成素 (Epo) 的生物学得到了极大的扩展，从循环红细胞量的调节剂到广泛使用的治疗剂。最初被视为负责红细胞生成的肾脏激素，最近在动物模型和临床试验中的体内研究表明，许多其他组织在不影响红细胞量的情况下局部产生 Epo。因此，不仅其造血活性，而且最近发现的非红细胞生成作用以及新的药物递送系统正在被彻底研究，以满足每种治疗方法的特定 Epo 释放要求。本综述重点介绍了以前类似综述提供的信息，并介绍了最近的实验方法，以描述过去几年在 Epo 药物递送方面取得的进展和未来展望。
